David J. Brooks

ORCID: 0000-0003-2602-2518
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Parkinson's Disease Mechanisms and Treatments
  • Neurological disorders and treatments
  • Alzheimer's disease research and treatments
  • Genetic Neurodegenerative Diseases
  • Neuroscience and Neuropharmacology Research
  • Dementia and Cognitive Impairment Research
  • Medical Imaging Techniques and Applications
  • Neuroinflammation and Neurodegeneration Mechanisms
  • Advanced MRI Techniques and Applications
  • Botulinum Toxin and Related Neurological Disorders
  • Advanced Neuroimaging Techniques and Applications
  • Neurological Disease Mechanisms and Treatments
  • Functional Brain Connectivity Studies
  • Epilepsy research and treatment
  • Neurotransmitter Receptor Influence on Behavior
  • Transcranial Magnetic Stimulation Studies
  • Galaxies: Formation, Evolution, Phenomena
  • Nerve injury and regeneration
  • Astronomy and Astrophysical Research
  • Traumatic Brain Injury and Neurovascular Disturbances
  • Neurological and metabolic disorders
  • Neurological diseases and metabolism
  • Nuclear Receptors and Signaling
  • Diet and metabolism studies
  • Glioma Diagnosis and Treatment

Aarhus University
2016-2025

Newcastle University
2016-2025

Aarhus University Hospital
2016-2025

University College London
2009-2025

Harvard University
2003-2025

University of Connecticut
2025

Creighton University
2025

Vanderbilt University
2025

Imperial College London
2015-2024

Newcastle Hospitals - Campus for Ageing and Vitality
2016-2024

<b>Background: </b> A consensus conference on multiple system atrophy (MSA) in 1998 established criteria for diagnosis that have been accepted widely. Since then, clinical, laboratory, neuropathologic, and imaging studies advanced the field, requiring a fresh evaluation of diagnostic criteria. We held second 2007 present results here. <b>Methods: Experts aspects MSA were invited to participate 2-day conference. Participants divided into five groups, consisting specialists parkinsonian,...

10.1212/01.wnl.0000324625.00404.15 article EN Neurology 2008-08-25

There is debate about whether the initial treatment for patients with Parkinson's disease should be levodopa or a dopamine agonist.

10.1056/nejm200005183422004 article EN New England Journal of Medicine 2000-05-18
Amir Aghamousa Jessica Aguilar Steve Ahlen Shadab Alam Lori Allen and 95 more Carlos Prieto J. Annis S. Bailey Christophe Balland O. Ballester C. Baltay Lucas Beaufore C. Bebek Timothy C. Beers Eric F. Bell José Luis Bernal Robert Besuner Florian Beutler Chris Blake Hannes Bleuler Michael Blomqvist Robert Blum A. Bolton César Briceño David J. Brooks Joel R. Brownstein E. Buckley‐Geer A. Burden Etienne Burtin Nicolás G. Busca R. N. Cahn Yan-Chuan Cai L. Cardiel-Sas Raymond G. Carlberg Pierre-Henri Carton R. Casas F. J. Castander Jorge L. Cervantes–Cota T. Claybaugh Madeline Close Carl T. Coker Shaun Cole Johan Comparat Andrew P. Cooper M.-C. Cousinou Martín Crocce Jean-Gabriel Cuby Daniel P. Cunningham Tamara M. Davis Kyle S. Dawson Axel de La Macorra Juan de Vicente Timothée Delubac Mark Derwent Arjun Dey Govinda Dhungana Zhejie Ding Peter Doel Yutong T. Duan Anne Ealet Jerry Edelstein Sarah Eftekharzadeh Daniel Eisenstein Ann Elliott S. Escoffier Matthew Evatt Parker Fagrelius Xiaohui Fan Kevin Fanning Arya Farahi Jay Farihi Ginevra Favole Feng Yu Enrique Fernandez Joseph Findlay Douglas P. Finkbeiner Michael J. Fitzpatrick B. Flaugher Samuel Flender Andreu Font-Ribera J. E. Forero-Romero P. Fosalba Carlos S. Frenk Michele Fumagalli Boris Gaensicke Giuseppe Gallo J. García-Bellido E. Gaztañaga N. P. Gentile Fusillo Terry Gerard Irena Gershkovich Tommaso Giannantonio Denis Gillet Guillermo Gonzalez-De-Rivera Violeta González-Pérez Shelby Gott Or Graur Gaston Gutierrez Julien Guy Salman Habib

DESI (Dark Energy Spectroscopic Instrument) is a Stage IV ground-based dark energy experiment that will study baryon acoustic oscillations (BAO) and the growth of structure through redshift-space distortions with wide-area galaxy quasar redshift survey. To trace underlying matter distribution, spectroscopic targets be selected in four classes from imaging data. We measure luminous red galaxies up to $z=1.0$. probe Universe out even higher redshift, target bright [O II] emission line $z=1.7$....

10.48550/arxiv.1611.00036 preprint EN other-oa arXiv (Cornell University) 2016-01-01

Abstract Probabilistic atlases of neuroanatomy are more representative population anatomy than single brain atlases. They allow anatomical labeling the results group studies in stereotaxic space, automated individual imaging datasets, and statistical assessment normal ranges for structure volumes extents. No such manually constructed atlas is currently available frequently studied young adults. We 20 subjects (10 women, median age 31 years) with high‐resolution magnetic resonance (MRI)...

10.1002/hbm.10123 article EN Human Brain Mapping 2003-05-30

We have used positron emission tomography to study the functional anatomy of motor sequence learning. Subjects learned sequences keypresses by trial and error using auditory feedback. They were scanned with eyes closed under three conditions: at rest, while performing a that was practiced before scanning until overlearned, learning new same rate performance. Compared both tasks activated contralateral sensorimotor cortex extent. Comparing performance prelearned sequence, differences in...

10.1523/jneurosci.14-06-03775.1994 article EN cc-by-nc-sa Journal of Neuroscience 1994-06-01

Abstract We have studied regional cerebral blood flow changes in 6 patients after their recovery from a first hemiplegic stroke. All had single well‐defined hemispheric lesion and at least brachial monoparesis that subsequently recovered. Each patient measurements of by positron tomography with 2 scans rest, during movement fingers the recovered hand, normal hand. When were moved, increased significantly contralateral primary sensorimotor cortex ipsilateral cerebellar hemisphere. hand...

10.1002/ana.410290112 article EN Annals of Neurology 1991-01-01

The reason for the high frequency of depression and anxiety in Parkinson's disease is poorly understood. Degeneration neurotransmitter systems other than dopamine might play a specific role occurrence these affective disorders. We used [11C]RTI-32 PET, an vivo marker both noradrenaline transporter binding, to localize differences between depressed non-depressed patients. studied eight 12 patients with without history matched age, duration doses antiparkinsonian medication. cohort had lower...

10.1093/brain/awh445 article EN Brain 2005-02-16

Abstract Objective Glial cell line–derived neurotrophic factor (GDNF) exerts potent trophic influence on midbrain dopaminergic neurons. This randomized controlled clinical trial was designed to confirm initial benefits observed in a small, open‐label using intraputamenal (Ipu) infusion of recombinant human GDNF (liatermin). Methods Thirty‐four PD patients were 1 receive bilateral continuous Ipu liatermin 15μg/putamen/day or placebo. The primary end point the change Unified Parkinson Disease...

10.1002/ana.20737 article EN Annals of Neurology 2006-01-20

Abstract Objective: Patient outcome after traumatic brain injury (TBI) is highly variable. The underlying pathophysiology of this poorly understood, but inflammation potentially an important factor. Microglia orchestrate many aspects response. Their activation can be studied in vivo using the positron emission tomography (PET) ligand [11C](R)PK11195 (PK). In study, we investigate whether inflammatory response to TBI persists, and relates structural abnormalities cognitive function. Methods:...

10.1002/ana.22455 article EN Annals of Neurology 2011-04-18

Abstract Preclinical studies suggest ropinirole (a D2/D3 dopamine agonist) may be neuroprotective in Parkinson's disease (PD), and a pilot clinical study using 18 F‐dopa positron emission tomography (PET) suggested slower loss of striatal storage with compared levodopa. This prospective, 2‐year, randomized, double‐blind, multinational the rates dopamine‐terminal function de novo patients PET evidence early PD, randomized 1 to receive either or The primary outcome measure was reduction...

10.1002/ana.10609 article EN Annals of Neurology 2003-06-25

Patients with Parkinson's disease tend to have a reduced response levodopa after 5 20 years of therapy, "on—off" fluctuations consisting dyskinesia alternating immobility. In an effort modify the motor disability advanced disease, we implanted embryonic mesencephalic tissue containing dopamine cells into caudate and putamen seven patients. Two patients received unilateral grafts in on side opposite worse symptoms. Five bilateral only. six patients, fetal was obtained from single embryo...

10.1056/nejm199211263272202 article EN New England Journal of Medicine 1992-11-26

Event-related potential studies in man suggest a role for the supplementary motor area (SMA) movement preparation, particularly when movements are internally generated. In previous study combining PET with recording of movement-related cortical potentials, we found similar SMA activation and early pre-movement negativity during self-initiated predictably paced index finger extensions. Early was absent were by unpredictable cues. We postulated that preparation preceding cued responsible...

10.1093/brain/123.6.1216 article EN Brain 2000-06-01
Coming Soon ...